Your browser doesn't support javascript.
loading
Clinical and Immunological Outcomes in High-Risk Resected Melanoma Patients Receiving Peptide-Based Vaccination and Interferon Alpha, With or Without Dacarbazine Preconditioning: A Phase II Study.
Urbani, Francesca; Ferraresi, Virginia; Capone, Imerio; Macchia, Iole; Palermo, Belinda; Nuzzo, Carmen; Torsello, Angela; Pezzotti, Patrizio; Giannarelli, Diana; Pozzi, Anna Fausta; Santaquilani, Mariano; Roazzi, Paolo; Bastucci, Silvia; Catricalà, Caterina; La Malfa, Antonia; Vercillo, Giuseppe; Gualtieri, Novella; Buccione, Carla; Castiello, Luciano; Cognetti, Francesco; Nisticò, Paola; Belardelli, Filippo; Moschella, Federica; Proietti, Enrico.
Afiliação
  • Urbani F; Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
  • Ferraresi V; Medical Biotechnology and Translational Medicine, Tor Vergata University, Rome, Italy.
  • Capone I; Department of Medical Oncology 1, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Macchia I; Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
  • Palermo B; Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
  • Nuzzo C; Unit of Tumor Immunology and Immunotherapy, Department of Research, Advanced Diagnostics and Technological Innovation, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Torsello A; Department of Medical Oncology 1, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Pezzotti P; Department of Medical Oncology 1, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Giannarelli D; Department of Infectious Disease, Istituto Superiore di Sanità, Rome, Italy.
  • Pozzi AF; Biostatistical Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Santaquilani M; Hospital Pharmacia, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Roazzi P; Computer Control and Management, Istituto Superiore di Sanità, Rome, Italy.
  • Bastucci S; Health Technology Assessement, Istituto Superiore di Sanità, Rome, Italy.
  • Catricalà C; Clinical Trial Center, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • La Malfa A; Oncological Dermatology, San Gallicano Hospital, Rome, Italy.
  • Vercillo G; Hospital Pharmacia, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Gualtieri N; Clinical Pathology, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Buccione C; Unit of Tumor Immunology and Immunotherapy, Department of Research, Advanced Diagnostics and Technological Innovation, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Castiello L; Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
  • Cognetti F; FAST-Istituto Superiore di Sanità, Rome, Italy.
  • Nisticò P; Department of Medical Oncology 1, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Belardelli F; Unit of Tumor Immunology and Immunotherapy, Department of Research, Advanced Diagnostics and Technological Innovation, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Moschella F; Institute of Translational Pharmacology, CNR, Rome, Italy.
  • Proietti E; Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
Front Oncol ; 10: 202, 2020.
Article em En | MEDLINE | ID: mdl-32211314
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2020 Tipo de documento: Article